eng Oriental Scientific Publishing Company Biomedical and Pharmacology Journal 0974-6242 2024-03-20 17 1 401 407 10.13005/bpj/2867 56521 article Balamurali Venkatesan 1 Leela Kakithakara Vajravelu 1 Sujith Ravi 1 Jayaprakash Thulukanam 1 Om Lokesh Muthamilan 2 Department of Microbiology, SRM Medical College Hospital and Research Centre, SRM Institute of Science and Technology, Kattankulathur, Chengalpattu district, Tamilnadu, India Department of Microbiology, Kasturba Medical College, 203, Light House Hill Road, Hampankatta, Mangalore, Karnataka, India Individuals with Type-2 diabetic mellitus (T2DM) along with several other disease-causing factors are impacted adversely by the SARS-CoV-2 pandemic. In India, BBV-152 (Covaxin^TM) and ChAdOx1-nCOV (Covishield^TM) vaccines are now being used to limit the spread of SARS-CoV-2 Infection. Adaptive immunity like humoral and T-cell-mediated immunity has a vital role in eliminating SARS-CoV-2. In order to control the disease's course, the infected cells are being destroyed predominantly by cytotoxic CD8+ T cells as well as specific antibodies against SARS-CoV-2 which have the potential to neutralize the virus. This cross-sectional study was done to identify the specific antibodies for SARS-CoV-2 in serum samples from those individuals with and without T2DM by using WANTAI SARS-CoV-2 Total Ab ELISA Kit. The present study comprises 354 study participants, among them T2DM was present in 141 (39.8%) cases and 213 (60.2%) were non-diabetic patients. Hypertension was observed in 95 (26.1%) participants and 259 (73.1%) participants were normotensive. The study participants with T2DM demonstrated lower levels of SARS-CoV-2 total antibodies having an average of 5 AU/ml over those individuals without diabetes showing an average of 12 AU/ml. Among the hypertensive patients, the total antibody levels of SARS-CoV2 are were substantially lowered to showing an average of 8 AU/ml as compared to normotensive subjects showing an average of 14 AU/ml. The results of the current study suggest that regular monitoring of the total SARS-CoV-2 antibody profile may be a useful strategy for assisting people with T2DM and hypertension in determining whether they require SARS-CoV-2 precautionary doses to maintain immunity and protect against infections. https://biomedpharmajournal.org/vol17no1/correlation-of-robust-immune-response-against-sars-cov-2-vaccine-among-diabetic-and-non-diabetic-participants/ Comorbidities Diabetic Non-diabetic SARS-CoV-2 Vaccines SARS-CoV-2 Total Antibody Levels